EarningsInsider
Posted - 09/28/23
RegeneRx Biopharmaceuticals Sees Short Interest Decrease from 19,400 shares to 11,800 shares. $RGRX https://www.marketbeat.com/stocks/OTCMK
Stock_Titan
Posted - 08/15/23
$RGRX RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations
https://www.stocktitan.net/news/RGRX/regene-rx-effects-reverse-stock-split-and-terminates-sec-reporting-iyhda72ckkph.html
cctranscripts
Posted - 08/14/23
Securities registration termination [Section 12(g)] https://www.conferencecalltranscripts.org/summary/?id=12455054 $RGRX
EarningsInsider
Posted - 08/07/23
RegeneRx Biopharmaceuticals, Inc. Files SEC Form 8-K $RGRX https://www.marketbeat.com/stocks/OTCMKTS/RGRX/sec-filings/
risenhoover
Posted - 08/07/23
$RGRX / Regenerx Biopharmaceuticals files form 8-K - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 REGENERX BIOPHARMA https://fintel.io/sf/us/rgrx?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing
dontu1dr
Posted - 9 months ago
$RGRX Hey JJ and RGRX Board,,, In the last 10Q (5/15/23) on page 22,,, under the heading "Our Strategy"": -RGN-352 IND has voluntarily been inactivated by the Company can you explain "exactly how much money" it costs to maintain that...??? Exact amount saved per year...??? Because the VERY IMPORTANT RESEARCH with: RGN-352 at the University of Arizona using TB4 on the HEART,,, just came on market: 6/22/23 & 5/24/23 And RGRX seems to have supplied TB4,,, for some of that technology... If RGRX paid attention to running the business,,, "voluntarily inactivating" RGN-352,,, right about the time someone is offering for sale: TB4 injectable for the heart Seems very questionable behavior... I'll add it to my already long list THE DONKER Yahoo wouldn't let me post
STCKPRO
Posted - 9 months ago
$RGRX NEW ARTICLE : RegeneRx To Extend Consent Solicitation Vote https://www.stck.pro/news/RGRX/57841283/
Stock_Titan
Posted - 9 months ago
$RGRX RegeneRx To Extend Consent Solicitation Vote
https://www.stocktitan.net/news/RGRX/regene-rx-to-extend-consent-solicitation-i9roqyropyyz.html
dontu1dr
Posted - 9 months ago
$RGRX Here's a very interesting job at NOVARTIS: novartis.com/careers/career... READ IT CLOSELY This job would fit the TB4 technology posted at to a T: -Deliver novel and drug-like molecules for treatment of cardiac arrhythmias; -co-lead a ground-breaking project in the arrhythmia portfolio. PAY ATTENTION TO THIS: HERE'S real KEY (or possible tell) in the job application under MINIMUN REQUIREMENTS: "experience with ion channels targets a plus" Go to the patent app: patents.google.com/patent/U... Do a word search for "ion channels" and you'll see that is how the TB4 TECHNOLOGY WORKS via: "potassium ion channel" AND: U of A just listed this Technology: Tech Launch Arizona on 6/22/23 Under: Cell Based Therapies for Arthythmias now: go to USPTO PATENT CENTER & ENTER application #: 16/629070 recently approved for a PATENT APPROVAL AND University of AZ mentions "Regenerx" in a # of patents and applications VERY INTERESTING SITUATION Show Less
dontu1dr
Posted - 07/29/23
$RGRX To those who Spoke with JJ about the "new plan" for RGRX: Go to SEC filing: DEF 14A 07/11/2023 page: 12 -Because the proposed amendment does not result in a reduction in the total number of shares of Common Stock that we are authorized to issue, the implementation of the reverse stock split will have the effect of increasing the number of available authorized shares of Common Stock -Because holders of our Common Stock have no preemptive rights to purchase or subscribe for any of our unissued Common Stock, the future issuance of additional shares of authorized Common Stock that will become newly available as a result of the implementation of the reverse stock split will reduce the current stockholders’ percentage ownership interest in the total outstanding shares of our Common Stock. 30 billion shares authorized "in DIRECT proportion" to the now 300 million shares authorize pre 100:1 split INSANE DILUTION POTENTIAL
EarningsInsider
Posted - 07/27/23
RegeneRx Biopharmaceuticals Sees Short Interest Decrease from 800 shares to 600 shares. $RGRX https://www.marketbeat.com/stocks/OTCMKTS/RGR
lisahageloh
Posted - 07/26/23
$RGRX Wow! Had a cool experience. I had questions about this up coming vote. I called RGRX and spoke directly to J.J. Finkelstein. He answered all my questions. I suggest you do too if you have any questions.
dontu1dr
Posted - 07/24/23
$RGRX UNIVERSITY of ARIZONA just had the TB4 PATENT APPROVED for TREATING CARDIAC ARRHYTHMIAS: https://patents.google.com/patent/US20200171206A1/en?oq=16%2f629070 look at CLAIM #26, very, very, broad coverage go to USPTO PATENT CENTER and ENTER application #: 16/629070 to follow this situation in real time... AND University of AZ mentions "Regenerx" in the following patents and applications in relation to "thymosin beta 4" (enter the following into google patents then do a search of "regenerx" in the patents or applications): US 9976123 B2 US 9976123 B2 US 20220306992 A1 this last patent application was published: 2022-09-29 Typically, Regenerx will only give the TB4 if they have a MTA (material transfer agreement) in place. THIS is RELEVANT to LONGS in REGENERX... but will RGRX DISCLOSE this info... It should/would be MATERIAL at this point in time,,, especially when they are talking about taking RGRX dark or private...??? THE DONKER
macroaxis
Posted - 07/21/23
$RGRX - Regenerx Biopharm In currently holds about 478.41 K in cash with (990.3 K) of positive cash flow from operations. https://www.macroaxis.com/stock-analysis/RGRX/Regenerx-Biopharm-In #insidertrading #stocks #fintechnews
dontu1dr
Posted - 07/18/23
$RGRX Look at page 2 and 3 of this document,,, then add the last promissory deal to it... Will these folks be the next owners of RGRX,,, when they decide not to fund PRIVATE RGRX...??? https://www.otcmarkets.com/otcapi/company/financial-report/371920/content That would be a very easy step once private... Notice Lee's Pharma would even be in line for the RGRX biologic win... THE DONKER
dontu1dr
Posted - 07/17/23
$RGRX INTERESTING SITUATION: https://www.businesspost.co.kr/BP?command=article_view&num=321373 ---WILL REGENERX be involved the REVERSE MERGER???
cctranscripts
Posted - 07/11/23
Other definitive proxy statements https://www.conferencecalltranscripts.org/summary/?id=12354582 $RGRX
dontu1dr
Posted - 07/11/23
$RGRX Here's what happened to EB skin trial that JJ didn't disclose to us or probably the folks in the Roth Deal: When they originally set up Gtreebnt they handpicked two CO-CEO's: W YANG PARK II In 2016, Park resigned and went to YuYang that was used as another BioTech Shell (same modus of operandi as Digital Aria shell became Gtreebnt). Then YuYang became largest holder of GTREEBNT STOCK and Yang signs over to Park II all TB4 skin rights (RGN-137)... JJ touted EB skin results but then went MUM. What happened with that situation? http://www.infostockdaily.co.kr/news/articleView.html?idxno=100930 Yuyang D&U was also adjusted from grade B to grade C due to the influence of former CEO Park Il's indictment of embezzlement and breach of trust charges and refusal of audit opinion. Yuyang was delisted off exchange and there was a forced sale of all Gtree stock on 3/20/20, the very day tb4 became a biologic: https://m.stock.naver.com/domestic/stock/115450/notice/1047141 There after: "let the games begin" with ownership in Korea and USA THE DONKER
dontu1dr
Posted - 07/11/23
$RGRX I wonder if RGRX used this PRESS RELEASE by YANG to encourage HEDGE FUNDS to BUY the ROTH OFFERING: http://www.press9.kr/news/articleView.html?idxno=47991 2021.05.17 (RIGHT BEFORE ROTH DEAL) Yang Won-seok, CEO of Gtree B&T: "RGN-259 can be approved as a new drug in the US" ---This was a total con job ---taking dry eye draft guidance out of context AND Regenerx should have known what was going in with their "partner" in S. Korea... THE DONKER
EarningsInsider
Posted - 07/10/23
RegeneRx Biopharmaceuticals, Inc. Files SEC Form 8-K $RGRX https://www.marketbeat.com/stocks/OTCMKTS/RGRX/sec-filings/
dividendinvestorbyeagle
Posted - 07/07/23
$RGRX close decreased > 10% (RegeneRx Biopharmaceuticals Inc) https://www.dividendinvestor.com/dividend-news/?symbol=rgrx http://dlvr.it/SrrvwW
cctranscripts
Posted - 07/06/23
Apta Finance SA just provided an update on activist position in REGENERX BIOPHARMACEUTICALS INC https://www.conferencecalltranscripts.org/summary/?id=12342293 $RGRX
dontu1dr
Posted - 07/06/23
@kampochea Thanks for that article on $RGRX...!!! damn shame we can't put that on yahoo... It would appear that HLB is moving slowly but maybe a lot more surely than Gtreebnt. thanks again, THE DONKER
dontu1dr
Posted - 07/06/23
$RGRX IR sheet from HLB S. KOREA: https://file.irgo.co.kr/data/BOARD/ATTACH_PDF/HX9WV5ZYC93MDF28Y6QZMKSAZ2RQ4U3K202376172024.pdf I cut parts on NK and ran thru google translate for a summary: RGN-259: NK Phase 3 Promotion Direction and Progress ✓ Simultaneous progress of two NK clinical phase 3 studies (SEER-2, SEER-3) ✓ Current progress - July 2022 CRO contract - SEER-2: First institution initiation meeting in December 2022, patient recruitment, first patient administration in April, clinical institution recruitment in progress. - SEER-3: Submit application for clinical trial approval in Europe and UK in February 2023 → European approval completed in June * Estimated time of clinical start: July 2023 (start of patient recruitment) Next: Number of subjects for each clinical study: about 70 Next: Expected time to complete patient recruitment - SEER-2: Q1 2024 - SEER-3 : Second half of 2024 Next: Drug repositioning decision for strategic approach in ARISE-4 (DRY EYE) clinical period by monitoring NK clinical progress and interim results THE DONKER
dontu1dr
Posted - 9 months ago
$RGRX Interim Results of NK trial could be announced tonight in S. Korea. https://mobile.newsis.com/view.html?ar_id=NISX20230704_0002363119 quote: """These efforts are yielding results. In the case of eye disease, it was decided to focus on the clinical trial of neurotrophic keratitis (NK), which has clear key evaluation variables. The phase 2 clinical trial is also cruising and the interim results are expected to be announced on the 6th of this month.""" THE DONKER
